Windlas Biotech Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹238.50 crore, reflecting a quarter-on-quarter *(QoQ) increase of 2.32 per cent from ₹233.10 crore. This corresponds to a year-on-year *(YoY) growth of 17.66 per cent.
Operating Profit
Operating Profit stands at ₹25.29 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.78 per cent from ₹24.37 crore. This corresponds to a year-on-year *(YoY) decline of 1.02 per cent.
PBDT
PBDT stands at ₹28.17 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.81 per cent from ₹27.67 crore. This corresponds to a year-on-year *(YoY) decline of 3.43 per cent.
Profit Before Tax
Profit Before Tax stands at ₹20.17 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.00 per cent from ₹19.97 crore. This corresponds to a year-on-year *(YoY) decline of 3.17 per cent.
Net Profit
Net Profit stands at ₹15.99 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.60 per cent from ₹15.00 crore. This represents a 1.78 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Windlas Biotech Ltd Earnings
- YOY
- QOQ
Windlas Biotech Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Windlas Biotech Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Windlas Biotech Ltd Financial Reports
Windlas Biotech Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Windlas Biotech | -2.90% | -9.63% | -15.99% | 8.28% | 6.50% | 1.35% |
| Panacea Biotec | -2.04% | -5.28% | -9.90% | -36.92% | -2.16% | -23.78% |
| Indoco Remedies | -2.42% | -9.88% | -8.28% | -10.43% | 1.95% | -24.59% |
| Syncom Formul. | -5.63% | -12.71% | 17.48% | 58.28% | 57.83% | 32.72% |
| Hester Bios | -0.83% | -3.97% | -4.05% | -13.22% | 44.32% | 21.85% |
| NGL Fine Chem | -1.10% | -8.75% | 11.34% | -8.78% | 22.51% | 87.39% |
| Titan Biotech | -0.88% | 0.81% | -3.95% | 2.74% | -7.17% | 52.94% |
Company Info
Company Information
Chairman & Independent Directo : Vivek Dhariwal
WTD & Executive Director : ASHOK KUMAR WINDLASS
Joint MD & Executive Director : MANOJ KUMAR WINDLASS
Executive Director & MD : HITESH WINDLASS
Independent Non Exe. Director : Gaurav Gulati
Non Executive Director : Prachi Jain Windlass
Executive Director : Pawan Kumar Sharma
Independent Non Exe. Director : Tarashree Singhal
Company Sec. & Compli. Officer : Ananta Narayan Panda